Tetrahydrocannabivarin (THCV) isolate, with a purity of 98% or higher. This THCV isolate is produced in an EU-GMP compliant facility within the European Union. EU-GMP certification is in progress and is expected in the second half of 2021.
This THCV isolate will be available from March 2021. If you are interested in this product, please contact us so we can send you all relevant documents.
Our pure and stable synthetic tetrahydrocannabivarin (THCV) is the latest addition to our product portfolio and it presents multiple opportunities for studying it in a variety of applications involving endocannabinoid receptors. Latest research supports its potential in the treatment of chronic diseases. The compound shows promise in pre-clinical studies as an anti-inflammatory, anti-psychotic, and neuro-protectant. Last but not least, THCV demonstrated highly promising results in the treatment of obesity and lowering blood sugar levels, making it an ideal candidate to replace drugs formerly developed in the area of weight control. Despite the challenging THCV synthesis path, the purity of THCV isolate developed by our team exceeds 98% purity.